AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling

Life Sciences

Volumn 80, Issue 1, 2006, Pages 82-88

  Oishi, Yoshihiko ^a   Ozono, Ryoji ^a   Yoshizumi, Masao ^a   Akishita, Masahiro ^b   Horiuchi, Masatsugu ^c   Oshima, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AT2; Myocardial infarction; Receptor; Valsartan; Ventricular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLE; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; HEART PROTECTION; KNOCKOUT MOUSE; LUNG CONGESTION; MALE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; RECEPTOR BLOCKING; SYSTOLE; WILD TYPE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BODY WEIGHT; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; ORGAN SIZE; RECEPTOR, ANGIOTENSIN, TYPE 2; SURVIVAL RATE; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33751344579     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.08.033     Document Type: Article

References (30)

1. Adachi Y., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Kawakami R., Nakanishi M., Nakagawa Y., Tanimoto K., Saitoh Y., Yasuno S., Usami S., Iwai M., Horiuchi M., and Nakao K. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107 19 (2003) 2406-2408
2. Akishita M., Yamada H., Dzau V.J., and Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications 261 2 (1999) 345-349
3. Akishita M., Iwai M., Wu L., Zhang L., Ouchi Y., Dzau V.J., and Horiuchi M. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102 14 (2000) 1684-1689
4. Booz G.W., and Baker K.M. Role of type 1 and type 2 angiotensin rReceptors in angiotensin II induced cardiomyocyte hypertrophy. Hypertension 28 4 (1996) 635-640
5. Carey R.M., Wang Z.Q., and Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35 1 (2000) 155-163
6. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet 360 9335 (2002) 752-760
7. Di Pasquale P., Bucca V., Scalzo S., Cannizzaro S., Giubilato A., and Paterna S. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart 81 6 (1999) 606-611
8. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., and Moye L. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet 355 9215 (2000) 1575-1581
9. Fuchs M., Hilfiker A., Kaminski K., Hilfiker-Kleiner D., Guener Z., Klein G., Podewski E., Schieffer B., Rose-John S., and Drexler H. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB Journal 17 14 (2003) 2118-2120
10. Harada K., Sugaya T., Murakami K., Yazaki Y., and Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100 20 (1999) 2093-2099
11. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., and Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377 6551 (1995) 744-747
12. Jugdutt B.I., and Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Molecular and Cellular Biochemistry 260 1-2 (2004) 111-118
13. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?: implications for therapeutic blockade of the renin-angiotensin system. Circulation 109 1 (2004) 8-13
14. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., and Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 Receptors. Journal of Clinical Investigation 99 8 (1997) 1926-1935
15. Liu Y.H., Yang X.P., Shesely E.G., Sankey S.S., and Carretero O.A. Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. Journal of American College of Cardiology 43 8 (2004) 1473-1480
16. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circulation Research 83 12 (1998) 1182-1191
17. Matsushima S., Ide T., Yamato M., Matsusaka H., Hattori F., Ikeuchi M., Kubota T., Sunagawa K., Hasegawa Y., Kurihara T., Oikawa S., Kinugawa S., and Tsutsui H. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113 14 (2006) 1779-1786
18. Oishi Y., Ozono R., Yano Y., Teranishi Y., Akishita M., Horiuchi M., Oshima T., and Kambe M. Cardioprotective role of AT2 receptor in post-infarction left ventricular remodeling. Hypertension 41 3 (2003) 814-818
19. Ozono R., Matsumoto T., Shingu T., Oshima T., Teranishi Y., Kambe M., Matsuura H., Kajiyama G., Wang Z.Q., Moore A.F., and Carey R.M. Expression and localization of angiotensin subtype receptor proteins in the hypertensive rat heart. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 278 3 (2000) R781-R789
20. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 4 (1990) 1161-1172
21. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M., and Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England Journal of Medicine 349 20 (2003) 1893-1906
22. Pourdjabbar A., Parker T.G., Nguyen Q.T., Desjardins J.F., Lapointe N., Tsoporis J.N., and Rouleau J.L. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. American Journal of Physiology. Heart and Circulatory Physiology 288 4 (2005) H1997-H2005
23. Spinale F.G., de Gasparo M., Whitebread S., Hebbar L., Clair M.J., Melton D.M., Krombach R.S., Mukherjee R., Iannini J.P., and Seung J. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. effects on left ventricular performance and neurohormonal systems. Circulation 96 7 (1997) 2385-2396
24. Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., and Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. Journal of Clinical Investigation 95 2 (1995) 651-657
25. Tsutsumi Y., Matsubara H., Ohkubo N., Mori Y., Nozawa Y., Murasawa S., Kijima K., Maruyama K., Masaki H., Moriguchi Y., Shibasaki Y., Kamihata H., Inada M., and Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circulation Research 83 10 (1998) 1035-1046
26. Voros S., Yang Z., Bove C.M., Gilson W.D., Epstein F.H., French B.A., Berr S.S., Bishop S.P., Conaway M.R., Matsubara H., Carey R.M., and Kramer C.M. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. American Journal of Physiology. Heart and Circulatory Physiology 290 3 (2006) H1004-H1010
27. Wharton J., Morgan K., Rutherford R.A., Catravas J.D., Chester A., Whitehead B.F., Leval M.R., Yacoub M.H., and Polak J.M. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. Journal of Pharmacology and Experimental Therapeutics 284 1 (1998) 323-336
28. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., and Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 1 (1987) 44-51
29. Wu L., Iwai M., Nakagami H., Li Z., Chen R., Suzuki J., Akishita M., de Gasparo M., and Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 22 (2001) 2716-2721
30. Xu J., Carretero O.A., Liu Y.H., Shesely E.G., Yang F., Kapke A., and Yang X.P. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40 3 (2002) 244-250